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AbstrAct
Objective The Assessment of Burden of COPD (ABC) tool 
supports shared decision making between patient and 
caregiver. It includes a coloured balloon diagram to visualise 
patients’ scores on burden indicators. We aim to determine 
the importance of each indicator from a patient perspective, 
in order to calculate a weighted index score and investigate 
whether that score is predictive of costs.
Design Discrete choice experiment.
setting and participants Primary care and secondary care 
in the Netherlands. 282 patients with chronic obstructive 
pulmonary disease (COPD) and 252 members of the general 
public participated.
Methods Respondents received 14 choice questions and 
indicated which of two health states was more severe. 
Health states were described in terms of specific symptoms, 
limitations in physical, daily and social activities, mental 
problems, fatigue and exacerbations, most of which had three 
levels of severity. Weights for each item-level combination 
were derived from a Bayesian mixed logit model. Weights 
were rescaled to construct an index score from 0 (best) 
to 100 (worst). Regression models were used to find a 
classification of this index score in mild, moderate and severe 
that was discriminative in terms of healthcare costs.
results Fatigue, limitations in moderate physical activities, 
number of exacerbations, dyspnoea at rest and fear of 
breathing getting worse contributed most to the burden of 
disease. Patients assigned less weight to dyspnoea during 
exercise, listlessness and limitations with regard to strenuous 
activities. Respondents from the general public mostly 
agreed. Mild, moderate and severe burden of disease were 
defined as scores <20, 20–39 and ≥40. This categorisation 
was most predictive of healthcare utilisation and annual 
costs: €1368, €2510 and €9885, respectively.
conclusions The ABC Index is a new index score for the 
burden of COPD, which is based on patients’ preferences. 
The classification of the index score into mild, moderate and 
severe is predictive of future healthcare costs.
trial registration number NTR3788; Post-results.
IntrODuctIOn
Chronic obstructive pulmonary disease 
(COPD) is a chronic disease that affects tens 
of millions of patients worldwide.1 Its impact 
on health and quality of life goes beyond 
airway limitation.2–4 To measure this impact, 
patient-reported outcome measures like the 
(Saint George’s Respiratory Questionnaire 
(SGRQ), the Chronic Respiratory Disease 
Questionnaire (CRQ), the COPD Assessment 
Test (CAT) and the Clinical COPD Question-
naire (CCQ) are increasingly used. These 
instruments measure symptoms, functional 
limitations and mental and social impact of 
the disease.
None of the instruments is preference based, 
in the sense that they have not valued the items 
in the questionnaire in comparison with other 
items. Instead, the answers of the CCQ, CAT 
and CRQ are aggregated into total and domain 
scores using equal weights for each item.5–7 The 
scores for the SGRQ were based on weights 
that were derived by asking patients to rate the 
distress caused by each symptom or limitation 
separately on a visual analogue scale, without 
any trade-offs between them.8–10
Recently, a new instrument, the Assessment 
of Burden of COPD (ABC) tool was developed 
to support shared decision making by patients 
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strengths and limitations of this study
 ► We developed the first index score for the burden 
of chronic obstructive pulmonary disease that is 
completely based on the importance that patients 
themselves assign to different items.
 ► Patients’ importance weights were elicited for a 
broad range of domains of the burden of disease, 
including symptoms, limitations in physical, daily and 
social activities, fatigue, number of exacerbations 
and mental health.
 ► Weights were elicited from patients treated in both 
primary care and secondary care.
 ► The burden-of-disease scores were predictive of 
future healthcare consumption and costs.
 ► Formal validation of this predictive performance 
against other instruments is not part of this study.
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Figure 1 Visualisation of the integrated health status of a COPD patient. A high and green balloon indicates a satisfactory 
score on that domain, a low red balloon indicates a poor score and orange balloons an intermediate score. Grey balloons are 
the balloons of previous visit providing the opportunity to monitor over time body mass index (BMI).
and physicians. It describes and measures burden of disease 
from a very broad perspective: ‘the physical, emotional, 
psychological and/or social experiences of a patient with 
COPD’.11 This includes symptoms, functional limitations, 
emotions, mental problems and fatigue. It consists of a 
patient questionnaire plus several objective observations 
and measurements, like lung function, body mass index 
(BMI), smoking and physical activity. The questionnaire 
was largely based on the CCQ5 supplemented by three 
questions about patients’ emotional distress and one on 
fatigue.11 The answers to the ABC questionnaire and the 
results of the objective measurements are visualised in the 
form of coloured balloons (see figure 1), which can assist 
a shared decision-making process between patients and 
healthcare professionals. The balloons are linked to a treat-
ment algorithm that suggests potential treatment options 
that can be discussed with the patients.
In an 18-month cluster randomised controlled trial 
(RCT), patients who were treated according to the ABC 
tool were more likely to experience an improvement 
disease-specific quality of life than patients in usual care.12 
Earlier, the ABC reliability and validity were established.13
In the current study, we aimed to determine the impor-
tance of each burden-of-disease item of the ABC, from a 
patient perspective, in order to calculate a weighted index 
score on a 0–100 scale. These importance weights were 
obtained in a discrete choice experiment (DCE), in which 
respondents were presented comprehensive descriptions 
of COPD-related health states based of a combination of 
items, instead of isolated items.
Additionally, we explored whether the ABC Index score 
could be used to develop a grouping of patients into mild, 
moderate, and severe burden of disease that is predictive of 
future healthcare utilisation and costs.
The resulting ABC Index score can be used to assess 
overall improvement or deterioration in patients, which 
is especially relevant when progress on some items coin-
cides with worsening on others. Furthermore, it can be 
used to describe the burden of disease in populations of 
patients, for instance in a medical practice or in a study, and 
to monitor change in burden of disease at a group level. 
Finally, it can be used in budget forecasts.
MethODs
study design
This study was designed as a DCE. It consisted of a series 
of pair-wise choice questions, in which two COPD patients 
were described. In each question, respondents were asked 
to assess which of the patients was in worse health (see 
figure 2). Both patients’ health states were described on the 
basis of items from the ABC questionnaire. In DCE terms, 
these are called the attributes, and each attribute had three 
severity levels. Analysing respondents’ choices makes it 
possible to quantify the relative weight of each attribute 
level.
Development of the Dce questionnaire
Choice of attributes and levels
Elements of the ABC were included in the DCE question-
naire if they were linked to the subjectively experienced 
burden of disease. For this reason, the objective assess-
ments of lung function, smoking behaviour, BMI and 
level of physical activity were excluded.
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Figure 2 An example of a choice question. Respondents were asked whether person A or B was doing worse. Descriptions 
of A and B were based on three domains (symptoms, limitations due to breathing problems and mental problems), plus fatigue 
and the number of exacerbations. Domains could be folded in (with all items at the same level) or folded out (with possible level 
differences within the domain).
The final questionnaire consisted of the following 15 
attributes: shortness of breath at rest, shortness of breath 
during physical activity, coughing, sputum productions 
(together forming the respiratory symptom domain), 
limitations in strenuous physical activities, limitations in 
moderate physical activities, limitations in daily activi-
ties, limitations in social activities (limitations domain), 
feeling depressed (down), fear of breathing getting 
worse, worrying, listlessness, tense feeling (mental prob-
lems domain), fatigue and exacerbations (each forming 
a separate domain).
The ABC has seven answer categories for most ques-
tions. This number is too large for a DCE, most impor-
tantly because it leads to too many different health states 
that would be too difficult to distinguish for the respon-
dents. For this reason, the number of levels of each 
attribute in the DCE was limited to three: (1) seldom or 
never, (2) regularly and (3) most times for the symptoms, 
mental problems and fatigue domains; (1) not or hardly 
limited, (2) moderately limited and (3) severely limited 
for the limitations domain; and 0, 1 and 2 exacerbations 
per year, for the exacerbation domain.
To further reduce the cognitive burden on respon-
dents, an innovative design using ‘folded-in’ domains was 
developed. A ‘folded-in’ domain means that the domain 
was presented as a whole and that all attributes within 
the domain had the same level. When a domain was fold-
ed-out, the attributes were presented separately and the 
levels could differ. Each respondent got 14 choice ques-
tions: six choice questions with all dimensions folded-in 
and  eight choice questions with one of the domains fold-
ed-out. The first folded-in question was a control question 
to test the respondent’s comprehension of the task. It was 
not included in the analysis. An example of a choice ques-
tion is given in figure 1. In this example, the symptoms 
domain is folded-out, while the limitations and mental 
problems domains are folded-in. The attribute levels are 
colour coded, with darker shades for the more severe 
levels.
The questionnaire was pilot tested in patients from the 
St. Franciscus Gasthuis in Rotterdam (n=10). The pilot 
led to a change in the presentation (ie, the layout) in the 
choice questions and informed the final wording of the 
question that patients were asked to answer (see figure 1).
Further details about the design are provided in the 
online supplementary file 2. 
respondents
Two groups of respondents were invited to take part 
in this study. The first group consisted of patients who 
participated in the RCT investigating the effectiveness 
of the ABC tool, regardless of whether they were in the 
experimental group or the control group.12 They were 
recruited in 56 healthcare centres across the Netherlands 
(39 primary care and 17 hospital care) between March 
2013 and May 2015 and interviewed between January and 
 o
n
 20 August 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-017831 on 26 December 2017. Downloaded from 
4 Goossens LMA, et al. BMJ Open 2017;7:e017831. doi:10.1136/bmjopen-2017-017831
Open Access 
Table 1 Respondents
Patients (n=282) General public (n=250)
Age (SD) 65.0 (8.3) 46.0 (16.7)
Male (%) 57 55
Education
  Low (%) 48 13.0
  Middle (%) 37 34.8
  High (%) 15 52.2
Current smoker 32%
Ex-smoker 62%
Never smoked 6%
 
COPD diagnosis (%) 100 8.3
FEV1, as % of predicted (SD) 60 (18)
GOLD 1* 12%
GOLD 2* 54%
GOLD 3* 31%
GOLD 4* 3%
Any exacerbations in year before study 49.8%
Number of exacerbations in in year before study (SD) 0.89 (1.15)
SGRQ (SD) 37 (19)
EQ-5D† (SD) 0.84 (0.16)
 
Any comorbidity‡ 31%
Asthma 5%
Diabetes mellitus 12%
Heart failure 6%
Osteoporosis 4%
Depression 4%
Malignity 2%
Other comorbidity 13%
 
Treated in general practitioner practice 61%
Treated by pulmonologist 39%
*Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage (1: forced expiratory volume in 1 s (FEV1) >80% of predicted, 2: 
FEV150%–80% of predicted, 3: FEV130%–50% of predicted, 4: <30% of predicted).
†EQ-5D, health-related quality of life (0=dead, 1=perfect health).
‡Comorbidities were only recorded for patients who were randomised to the intervention group in the ABC trial (n=136).
COPD, chronic obstructive pulmonary disease; SGRQ, Saint George’s Respiratory Questionnaire (0–100, higher is worse).
June 2015. All patients had a physician-confirmed diag-
nosis of COPD (postbronchodilator forced expiratory 
volume in 1 s (FEV1)/forced vital capacity <0.7), were at 
least 40 years of age and had the ability to understand 
and read the Dutch language. The only exclusion criteria 
were: exacerbation less than 6 weeks before initiation 
of the study, a hard-drug addiction, a life-threatening 
comorbid condition or pregnancy at the start of the study.
All interviews were held after the patients had 
completed the trial. As part of the clinical trial, the 
self-reported COPD-related healthcare utilisation was 
reported every 3 months. The second group consisted 
of a representative sample (in terms of age, gender and 
education level) of members of the general public, who 
were approached through a respondents recruiting firm. 
Respondents were interviewed over the telephone by 
trained researchers from Erasmus University Rotterdam 
according to a standard protocol and received a €20 
reward after completing the interview. Interviews took 
approximately 30 min per respondent. Questionnaires 
were sent to respondents by mail or email before the 
interview took place.
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Table 2 Regression results. Bayesian mixed logit model of choice behaviour, mean preference weights per respondent group 
for each attribute level*
Attributes and domains
Respondent group
Level
Patients General public
Coefficient 95% CI** Coefficient 95% CI**
Exacerbations Once a year 0.815 0.516 to 1.162 1.513 1.125 to 1.961
Twice a year 2.243 1.744 to 2.881 2.641 2.073 to 3.312
Fatigue Regularly 1.189 0.876 to 1.545 1.023 0.702 to 1.383
Most times 2.103 1.662 to 2.652 2.377 1.854 to 2.983
Symptoms
  Dyspnoea at rest Regularly 0.497 −0.027 to 1.051 0.361 −0.206 to 0.987
Most times 1.848 1.092 to 2.732 1.024 0.236 to 1.877
  Dyspnoea during exercise Regularly 0.417 −0.245 to 1.103 0.629 −0.076 to 1.375
Most times 0.589 −0.077 to 1.288 1.480 0.716 to 2.325
  Coughing Regularly 0.220 −0.347 to 0.796 1.003 0.453 to 1.609
Most times 0.583 −0.028 to 1.217 1.284 0.648 to 1.980
  Sputum Regularly 0.946 0.494 to 1.459 0.550 0.077 to 1.061
Most times 0.662 0.066 to 1.273 1.551 0.919 to 2.282
Limitations
  Strenuous physical activities Moderately 0.899 −0.074 to 1.902 0.753 −0.404 to 1.888
Severely 1.141 0.050 to 2.270 1.186 −0.069 to 2.434
  Moderate physical activities Moderately 1.233 0.392 to 2.112 1.077 0.131 to 2.195
Severely 2.081 1.029 to 3.203 2.128 0.941 to 3.588
  Daily activities Moderately 0.518 0.008 to 1.043 0.434 −0.110 to 1.010
Severely 1.672 0.847 to 2.591 1.398 0.444 to 2.384
  Social activities Moderately 0.397 −0.120 to 0.942 0.709 0.163 to 1.314
Severely 1.534 0.691 to 2.453 1.769 0.819 to 2.781
Mental problems
  Fearing breathing problems Regularly 0.779 0.299 to 1.287 0.844 0.291 to 1.439
Most times 1.738 1.049 to 2.541 1.895 1.060 to 2.778
  Feeling depressed Regularly 0.073 −0.429 to 0.593 1.227 0.653 to 1.864
Most times 0.872 0.326 to 1.470 1.923 1.294 to 2.654
  Listlessness Regularly 0.526 0.009 to 1.045 0.385 −0.173 to 0.987
Most times 0.614 0.068 to 1.185 1.159 0.523 to 1.875
  Tense feeling Regularly 0.893 0.400 to 1.434 0.215 −0.343 to 0.778
Most times 1.056 0.360 to 1.814 1.227 0.441 to 2.082
  Worrying Regularly 0.456 −0.090 to 0.997 0.863 0.320 to 1.446
Most times 0.953 0.251 to 1.693 0.652 −0.122 to 1.484
*Higher weights mean more disutility of this attribute level compared with the reference value (none; never/hardly ever; hardly/not at all).
**95%CI, 95% confidence interval .
Ethics approval was obtained from the Medical Ethics 
Committee of Zuyderland Hospital, Heerlen, the 
Netherlands.
Analysis
A Bayesian mixed logit regression model was developed to 
estimate the contribution of each attribute-level combina-
tion to the probability that a patient was considered to be in 
a worse health state. The regression model included coeffi-
cients for all attribute levels. A mixed logit model takes into 
account that respondents answered several questions and 
that preferences across respondents may be heterogeneous. 
In addition, our regression model accounts for potential 
increases in the complexity of questions with a folded-out 
domain and for the possibility that a folded-out domain 
would get more weight than folded-in domains (see online 
supplementary file 1).
The analysis was repeated on the sample of members 
from the general public.
calculating the Abc Index score
The adjusted regression coefficients from the patient 
data were used to develop a 0 (best) to 100 (worst) scale. 
This process consisted of three steps: (1) regression, as 
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Table 3 ABC Index scores. Contribution of each domain item to the total ABC Index score, per severity level*
 None One Two or more
Exacerbations per year  0 4 1
Never Hardly ever A few times
Several 
times Many times
A great 
many times
Almost all 
the time
Fatigue per week 0 2 4 6 7 9 11
Symptoms per week
  Dyspnoea at rest 0 1 2 3 6 8 10
  Dyspnoea during exercise 0 1 1 2 2 3 3
  Coughing 0 0 1 1 2 2 3
  Sputum 0 1 2 2 2 3 3
Mental problems per week
  Fearing breathing problems 0 1 3 4 6 8 9
  Feeling depressed 0 0 0 1 2 4 5
  Listlessness 0 1 2 2 2 2 2
  Tense feeling 0 2 3 4 4 5 5
  Worrying 0 1 2 2 3 4 5
Not at all Very slightly Slightly Moderately Very Extremely Totally
Limitations
  Strenuous physical 
activities
0 2 3 4 4 5 5
  Moderate physical 
activities
0 2 4 6 8 9 11
  Daily activities 0 1 2 3 5 7 9
  Social activities 0 1 1 3 5 7 9
patient’s ABC Index score is the sum of the scores per domain, with a minimum of 0 and a maximum of 100.
described above, (2) linear interpolation of coefficients 
and (3) rescaling coefficients.
The original ABC questionnaire presents attributes on 
a seven-point scale, while the DCE contained only three 
levels per attribute. For this reason, the coefficients of 
the DCE attribute levels were linearly interpolated, in the 
second step, in order to create preference weights for all 
levels in between.
In the third step, the coefficients for the highest levels 
were combined to represent the unscaled index score 
for the worst possible burden of disease. This was then 
rescaled to a value of 100. Finally, all coefficients were 
rescaled accordingly and rounded to the nearest integer. 
As a result, the ABC Index will always be between 0 and 
100.
Predicting healthcare utilisation and costs
The capability of the ABC Index to predict health-
care utilisation and costs was explored by dividing the 
ABC Index into three categories (mild, moderate and 
severe burden of disease) and comparing the average 
resource utilisation and costs per category.
All relevant costs related to pulmonary disease 
from the healthcare perspective were included in 
the analysis. These included primary care, hospital 
care (outpatient contacts, admissions, intensive care, 
emergency room and ambulance), paramedical care 
(physiotherapist, dietitian and psychologist) and 
medication. Costs were calculated in euros (price 
level 2014) per 3-month period by multiplying a 
unit cost price with the number of resources used, as 
self-reported by the patients in a 3-montly resource 
utilisation questionnaire (see table A1 in online 
supplementary file 2).14 15
For the purpose of determining the most discrim-
inative classification, 3-month costs and 1-year costs 
directly after ABC measurement were analysed in 
regression models with the burden of disease cate-
gory as the explanatory variable. This was repeated 
for different cut-off points between categories. The 
1-year costs were regressed in ordinary leased squares 
models. The 3-month costs were analysed in multi-
level models (linear models with correlated errors), 
since there were several measurements per patient. 
The choice of the most appropriate cut-off points was 
determined based on the proportion of cost variance 
that was explained by the burden-of-disease categories 
(R-squared, for 1-year costs) and the Akaike Informa-
tion Criterion (for 3-month costs). Cut-off points were 
only considered appropriate if each group contained 
at least 10% of the observations.
Costs as well as healthcare resource use were 
compared per burden-of-disease category for primary 
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Figure 3 Distribution of ABC Index scores in sample. ABC, Assessment of Burden of COPD.
Table 4 Mean (SD) 3-month healthcare costs (in 2014 
euros) by burden of disease group
Total costs Costs of curative care*
Mild 380 350
Moderate 912 536
Severe 2678 1009
*Excluding home care and rehabilitation.
care, hospital care, paramedical care and medication. 
All statistical analysis were performed in Stata V.14.1 
and OpenBugs.
results
respondents
In the RCT investigating the effectiveness of the ABC 
tool, 370 patients were included. All 328 patients with 
COPD who stayed in the trial for at least 6 months were 
approached. The great majority (86%, 282 people) were 
willing and able to participate in the DCE. Table 1 shows 
that the characteristics of the respondents from the trial 
were different from those of the general public. COPD 
patients were older on average, with less variation in age 
and less educated. A sizeable proportion of patient group 
had one or more comorbidities. Some of the respondents 
from the general public stated that they were patients 
with COPD themselves.
Importance weights
Table 2 shows the results of the regression analyses for 
patients and the general public, respectively. Two coeffi-
cients per item or domain are presented: one for level 1 
(moderate problems) and one for level 2 (severe prob-
lems). A positive coefficient indicates that respondents 
considered this level worse compared with level 0 (no or 
hardly any problems). A larger coefficient means that the 
attribute contributes more to the burden of disease.
All coefficients for the items and domains had the 
expected positive sign and almost all were significantly 
different from 0, especially at high levels.
Patients and members of the general public had similar 
but not equal preferences. Both attached much weight 
to the number of exacerbations, fatigue, limitations in 
moderate physical activities and fear of breathing getting 
worse. A striking difference is that patients consid-
ered dyspnoea at rest more important than dyspnoea 
during exercise, whereas members of the general public 
reported the opposite. The latter group also put more 
emphasis on symptoms than on limitations, in contrast 
to patients.
Abc Index scores
The ABC Index scores are presented in table 3. A patient 
receives a score for each item. The total ABC Index score 
is the sum of all item scores. The maximum ABC Index 
score, for the worst possible health state, is 100. The 
minimum score, indicating no problems at all, is 0.
The items with the largest contribution to a high total 
score are fatigue, limitations while doing moderate phys-
ical activities, exacerbations and dyspnoea at rest. Other 
important items are fear for breathing getting worse and 
limitations in social and daily activities.
Figure 3 shows the distribution of the ABC Index 
scores over all observations of patients in the interven-
tion group of the RCT. Note that the ABC tool was not 
administered in the control group. The mean ABC Index 
score was 28.6 (SD: 14.3). The scores ranged from 1 to 
81, with a skew to the right. Three quarters of scores were 
below 37.
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Table 5 Average 3-month healthcare use by burden of disease group
General practitioner  contacts
Office hours Evening/weekend
Consult Phone call Home visit Consult Phone call Home visit
  Mild (0–19 points)* 0.19 0.05 0.01 0.22 0.09 0
  Moderate (20–39) 0.55 0.37 0.03 0.32 0.28 0.005
  Severe (40–100) 0.97 0.90 0.38 0.39 0.23 0.13
Hospital contacts Outpatient visits ER Ambulance rides Inpatient days ICU days
  Mild (0–19 points) 0.15 0 0 0 0
  Moderate (20-39) 0.28 0.05 0.01 0.10 0.02
  Severe (40-100) 0.77 0.27 0.11 0.47 0
Contacts with paramedical 
caregivers Physiotherapy Dietitian Psychologist
  Mild (0–19 points) 3.79 0.02 0.04
  Moderate (20–39) 4.46 0.23 0.32
  Severe (40–100) 8.53 0.46 0.62
Medication costs All medication Oral corticosteroids Antibiotics
  Mild (0–19 points) 189 0.28 0.66
  Moderate (20–39) 218 2.37 2.73
  Severe (40–100) 261 5.13 6.60
*Points on the Assessment of Burden of COPD Index.
ER, emergency room; ICU, intensive care unit.
Abc groups and healthcare utilisation
The ABC Index score was best grouped into a mild, 
moderate and severe burden of disease when using cut-off 
points at 20 and 40 points. This grouping had the best fit 
(AIC) and explained variance (R-squared) for 1-year costs 
and good AIC for 3 months (see online supplementary 
file 1). Table 4 shows that average healthcare costs were 
clearly higher for higher burden-of-disease groups.
The discrimination between the groups in terms of 
healthcare utilisation in the 3-month periods following an 
ABC measurement is good. Across all types of healthcare 
utilisation, utilisation increased as the burden of disease 
increased (table 5). General practitioners hardly ever 
visited patients at home who were not in the severe group. 
Patients with mild or moderate burden of disease used 
hardly any hospital care, with the exception of outpatient 
visits. With regards to paramedical care, healthcare use 
was strongly related to the experienced burden of disease 
again, with increasing amounts of care with increasing 
severity. Differences in medication costs across groups 
were small, although an increasing pattern is still visible. 
Patients in the mild groups had very few exacerbations, 
which is shown by the small numbers of courses of oral 
corticosteroids and antibiotics. Severe patients had more 
courses of these medicines than moderate patients.
DIscussIOn
This study developed the Dutch tariff for the ABC Index, 
a 0–100 scale that quantifies the burden of disease of 
patients with COPD. It showed the relative importance of 
the items that can be used to measure a COPD patient’s 
perceived burden of disease.
Patients with COPD attached the greatest weight on 
severe limitations in moderate physical activities, fatigue, 
dyspnoea at rest, fear of breathing getting worse and exac-
erbations. However, patients seem not very concerned 
about dyspnoea during exercise, listlessness and limita-
tions with regard to strenuous activities. It is plausible that 
they have learnt to accept these problems, consider these 
a given, and have found ways to cope with them. Patients 
and members of the general public mostly agreed about 
the relative weights, but in the general public symptoms 
(eg, coughing, sputum) contributed more to the burden 
of disease than it did in patients.
The results suggest that limitations in physical, daily 
and social activities, fear of breathing problems and 
fatigue should play a more important role as outcome 
measures in clinical trials of COPD therapies. Currently, 
the principle outcomes are often lung function, exacerba-
tions and mortality. When health status or health-related 
quality of life is measured, the dimensions identified as 
most relevant in this study, should be included. Several 
instruments do so, but their weights are commonly not 
based on the preferences of patients, as they explicitly 
were in the ABC Index. This makes the ABC Index an 
attractive candidate outcome measure for use in clinical 
trials.
Besides this use in a research setting, the ABC Index 
could be used to monitor the change over time, in 
either the mean score or the distribution over the 
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burden-of-disease classes, at practice level or care group 
level. Furthermore, at an individual patient level, it can be 
used to assess the overall change in experienced burden 
of disease, especially when some elements improve, 
whereas others deteriorate. This is only valid when the 
mean importance weights represent that individual’s 
preferences.
Burden of disease as expressed by the ABC Index can 
be used to predict individual healthcare costs. In our 
study, the most predictive grouping into three categories 
was: mild burden of disease (ABC Index 0–19), moderate 
(20–39) and severe (40–100). This classification is predic-
tive of healthcare costs, as well as all types of healthcare 
utilisation. Average 3-month costs for patients in the most 
severe category was three times the costs in the moderate 
category, and seven times the costs in the mild category. 
The strong association with healthcare utilisation and 
costs indicates that the ABC Index may also be useful 
for contracting of care between insurers and healthcare 
providers.
The association of the ABC Index and healthcare use 
confirms that patients with a higher burden of disease 
are also more severely ill. This could be considered as 
evidence of convergent validity of the ABC Index.
The main strength of this study is that the importance 
weights of a large number of items contributing to the 
burden of COPD were based on trade-offs between 
the items made by patients. Hence, the weights repre-
sent patients’ preferences. They were representative of 
Dutch patients with COPD, given their distribution over 
the country and because they were recruited from both 
primary and secondary care settings.
The ABC Index is different from severity indicators of 
COPD, like the Body-mass index, airflow Obstruction, 
Dyspnea and Exercise (BODE) Index and the variations 
thereof, which include characteristics that were selected 
based on their ability to predict future outcomes like 
mortality or disease progression. The ABC Index is 
not a severity indicator but a measure of the burden 
of disease as experienced by the patients with COPD. 
Compared with health status measures like the SGRQ, 
the CCQ and the CAT, it is the only instrument in which 
the weights of the items is entirely based on COPD 
patients’ preferences. Unlike the EQ-5D, which is a 
generic preference-based instrument, the ABC Index is 
a disease-specific preference-based instrument. It does 
not measure utilities for use in cost-utility analyses, like 
the EQ-5D does.
Our study has some limitations. One is its modest sample 
size, determined by the sample size of the RCT. This leads 
to some uncertainty in the estimates of resource utilisa-
tion and healthcare costs. The costing study should be 
viewed as evidence for the predictive performance of the 
ABC Index and a first step in a validation process, not as 
a definitive and precise estimate of healthcare utilisation 
and costs. Furthermore, given the fact that patients are 
treated differently in different countries, cost estimates 
are especially country-specific.
It is not certain whether the preference weights 
would be materially different in other countries or in 
different samples of COPD patients, but it is conceiv-
able that preferences are linked to individual experi-
ence. However, the similarity of the results of patients 
and members of the general public suggest that the 
results are robust to selection effects.
A further limitation is that the DCE questionnaire 
did not distinguish between exacerbations of different 
severities. It was based on the ABC tool and CCQ ques-
tionnaires, which do not make the distinctions either. 
Respondents were instructed to consider that exacer-
bations were periods of several days with extra breath-
lessness, whichin extreme cases could lead to hospital 
admissions.
In conclusion, the ABC Index score is an overall 
score of the experienced burden of disease that is 
based on the importance that patients themselves 
assign to the various items. The ABC Index score can 
be used to group patients into mild, moderate and 
severe burden of disease, and this grouping is predic-
tive of their future healthcare utilisation and costs. 
Hence, at a group level, the ABC Index can be used 
for monitoring, and it may guide contracting between 
health insurers and healthcare providers.
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